SCHEMBL10242690

SCHEMBL10242690

CC(=O)c1ccnn1-c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.51
CYP2C9 P11712 5/20 0.49
POLB P06746 2/20 0.48
HCRTR1 O43613 1/20 0.46
HCRTR2 O43614 1/20 0.46
GLS O94925 1/20 0.46
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
ROCK1 Q13464 1/20 0.42
CYP2C18 P33260 2/20 0.42
CYP2C19 P33261 1/20 0.42
BACE1 P56817 1/20 0.42
NR4A3 Q92570 1/20 0.41
GRN P28799 1/20 0.41
SORT1 Q99523 1/20 0.41
CYP2C8 P10632 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL856957 0.85 POLB (0.52) MAPK1CYP2C9POLBHCRTR1HCRTR2
Hydrochloric Acid SCHEMBL11893514 0.83 POLB (0.50) MAPK1CYP2C9POLBHCRTR1HCRTR2
SCHEMBL27637327 0.82 PTGS2 (0.50) ALDH1A1
SCHEMBL193205 0.81 POLB (0.48) MAPK1CYP2C9POLBHCRTR1HCRTR2
SCHEMBL3168308 0.81 POLB (0.53) CYP2C9POLBHCRTR1HCRTR2GLS
SCHEMBL25110209 0.81 GLS (0.52) MAPK1CYP2C9POLBHCRTR1HCRTR2
SCHEMBL17321503 0.81 ALDH1A1 (0.46) MAPK1CYP2C9POLBHCRTR1HCRTR2
SCHEMBL18394893 0.81 TP53 (0.50) CYP2C9POLBHCRTR1HCRTR2GLS
SCHEMBL13485755 0.79 GLS (0.53) CYP2C9POLBHCRTR1HCRTR2GLS
SCHEMBL31569567 0.77 ALDH1A1 (0.46) POLBALDH1A1ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9957281-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2018-05-01 US disclosed
US-20170022221-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2017-01-26 US disclosed
EP-2604597-B1 HETEROCYCLIC COMPOUND AND USE THEREOF INHIBITOR OF PHOSPHODIESTERASE 10A TAKEDA PHARMACEUTICALS CO (JP) 2017-01-04 EP disclosed
US-20150353505-A1 PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2015-12-10 US disclosed
US-9150588-B2 Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-10-06 US disclosed
EP-2631238-A1 Spirocyclic inhibitors of serine proteases for the treatment of hcv infections VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-08-28 EP disclosed
EP-2604597-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2013-06-19 EP disclosed
US-20130137675-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-30 US disclosed
US-8148373-B2 Compounds ASTRAZENECA AB (SE) 2012-04-03 US disclosed
US-20090298807-A1 Compounds ASTRAZENECA AB (SE) 2009-12-03 US disclosed
CN-1046724-C Pyrazolopyridine compounds, pharmaceutical compositions containing them, processes for their preparation and their use FUJISAWA PHARMACEUTICAL CO (JP) 1999-11-24 CN disclosed
CN-1139928-A Novel compounds FUJISAWA PHARMACEUTICAL CO (JP) 1997-01-08 CN disclosed
CN-1031570-C Pyrazolopyridine compound and processes for preparation thereof FUJISAWA PHARMACEUTICAL CO (JP) 1996-04-17 CN disclosed
CN-1044656-A Pyrazolopyridine compound and preparation method thereof FUJISAWA PHARMACEUTICAL CO (JP) 1990-08-15 CN disclosed
CN-1031376-A Pyrazolopyridine compound and preparation method thereof FUJISAWA PHARMACEUTICAL CO (JP) 1989-03-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353505-A1 PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS MYLK, MYLK2, ROCK1 MAPK1 163/4885CYP2C9 2835/4885POLB 3821/4885
US-20130137675-A1 HETEROCYCLIC COMPOUND AND USE THEREOF PDE3A, PDE2A, PDE5A MAPK1 210/4885CYP2C9 487/4885POLB 2535/4885
US-20170022221-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS GABRA5, GABRA1, GABBR2 MAPK1 2860/4885CYP2C9 62/4885POLB 4513/4885
US-20090298807-A1 Compounds PKD1, SLC10A1, ABCB11 MAPK1 2982/4885CYP2C9 22/4885POLB 3862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.